AHA: Statins Cut Risk of MACE in Patients With ASCVD Event

This article originally appeared here.
Share this content:
AHA: Statins Cut Risk of MACE in Patients With ASCVD Event
AHA: Statins Cut Risk of MACE in Patients With ASCVD Event

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- For patients who have experienced an atherosclerotic cardiovascular disease (ASCVD) event, receipt of statins, especially high-intensity statins, is associated with reduced risk of major adverse cardiac events (MACE), according to a study presented at the American Heart Association's Scientific Sessions, being held Nov. 11 to 15 in Anaheim, California.

Jeffrey L. Anderson, M.D., from the Intermountain Medical Center Heart Institute in Salt Lake City, and colleagues identified adults with a first encounter for ASCVD who survived the index event and were followed for three or more years or until death; 62,070 patients met the entry criteria.

The researchers found that 70.5 percent of patients were prescribed a statin, with 7.7, 75.8, and 16.5 percent receiving low-, moderate-, and high-intensity doses, respectively. Only 12.9 percent of those aged younger than 76 years on a known-intensity statin received high-intensity therapy as per current guidelines. The frequency of three-year MACE was 33.1 and 25.1 percent for those not prescribed and prescribed statins (multivariable hazard ratio, 0.89). The frequency of MACE varied with statin intensity and was 22.5, 19.2, and 17.3 percent for those receiving low-, moderate-, and high-intensity statins (moderate versus low: hazard ratio, 0.91; high versus low: hazard ratio, 0.88).

"Significant reductions in MACE were found in association with both any statin prescription and especially high-intensity statin following an ASCVD event in a large real-world experience," the authors write.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »